Boston Scientificvs.Stryker
BSX vs SYK · both in Medtech & devices, part of the Medicine, pharma & life science value chain: Medical equipment and devices, from surgery and cardiology to robotics.
Stryker is about 1.7× larger than Boston Scientific by market cap; Boston Scientific trades at the lower P/E (16.5 vs 28.0); year to date, Stryker leads (−21.6% vs −56.4%).
Side by side
| BSX | SYK | |
|---|---|---|
| Market cap | $60.7B | $105B |
| Price | $42.04 | $276.97 |
| Today | +1.1% | +0.6% |
| Return YTD | −56.4% | −21.6% |
| Return 1Y | −56.6% | −25.4% |
| Since June 26, 2026 | −5.0% | −16.8% |
| P/E | 16.5 | 28.0 |
| P/S | 2.9 | 4.0 |
| P/B | 2.4 | 4.4 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Boston ScientificBSX
Cardiology drives the growth, particularly electrophysiology, where Farapulse sits, and structural heart treatment. Endoscopy and urology cover the rest of the range.
Full BSX profile →StrykerSYK
Orthopaedic implants and surgical equipment, with Mako bringing robot assistance into the operating room.
Full SYK profile →More BSX & SYK comparisons
Other head-to-heads in the Medtech & devices segment.